BHC Bausch Health Companies Inc.

14.62
+1.31  (+10%)
Previous Close 13.31
Open 13.98
Price To Book 4.42
Market Cap 5,166,066,387
Shares 352,126,241
Volume 6,191,134
Short Ratio 3.42
Av. Daily Volume 5,575,377
Stock charts supplied by TradingView

NewsSee all news

  1. Bausch Health Companies Inc. Will Hold Virtual Annual Meeting Of Shareholders On April 28

    LAVAL, Quebec, April 2, 2020 /PRNewswire/ -- Bausch Health Companies Inc. (TSX:BHC) ("Bausch Health" or the "Company") announced today that, due to the emerging public health impact of the COVID-19

  2. Bausch Health Announces Favorable Topline Results From Study Evaluating Investigative Formulation of Rifaximin SSD IR to Treat Overt Hepatic Encephalopathy

    Study Arm Evaluating 40 MG BID of Rifaximin SSD IR In Combination with Standard of Care Therapy Met Primary Endpoint LAVAL, Quebec, March 31, 2020 /PRNewswire/ -- Bausch Health Companies Inc. (TSX:BHC) ("Bausch

  3. Bausch Health Donates Health Care Products And Supplies Through Bausch Foundation In Response To COVID-19 Pandemic

    LAVAL, Quebec, March 24, 2020 /PRNewswire/ -- Bausch Health Companies Inc. (TSX:BHC) ("Bausch Health" or the "Company") today outlined several initiatives the Company is taking to contribute to the fight

  4. Bausch Health To Reduce Debt By Approximately $100 Million Using Cash Generated From Operations

    LAVAL, Quebec, March 13, 2020 /PRNewswire/ -- Bausch Health Companies Inc. (TSX:BHC) ("Bausch Health" or the "Company") today announced it will reduce debt by approximately $100 million through the

  5. Bausch Health Announces It Will No Longer Pursue Proposed Refinancing Transaction And Also Announces Cancellation Of Previously Delivered Notice Of Conditional Redemption

    LAVAL, Quebec, March 2, 2020 /PRNewswire/ -- Bausch Health Companies Inc. (TSX:BHC) ("Bausch Health" or the "Company") announced today that, due to market conditions, it has determined to not pursue the

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Approval announced May 7, 2018.
Plenvu (NER1006)
Bowel cleansing
Approval announced November 2, 2017.
Latanoprostene bunod
Open angle glaucoma (OAG) or ocular hypertension (OHT)
FDA approval announced February 25, 2019.
Loteprednol Gel 0.38%
Ocular Inflammation
Approval announced December 22, 2017.
LUMIFY (brimonidine tartrate ophthalmic solution 0.025%)
Eye Brightener
FDA Approval announced August 24, 2018.
IDP-121
Acne
Tentative FDA Approval announced October 8, 2018. Final approval expected November 2018 pending the expiration of exclusivity for a related product.
IDP-122
Psoriasis
Phase 3 trial ongoing.
IDP-120
Acne
FDA approval announced April 25, 2019.
DUOBRII (halobetasol propionate and tazarotene)
Psoriasis
FDA Approval announced December 19, 2019.
IDP-123
Acne
Approved February 15, 2017.
Brodalumab
Psoriasis
CRL received October 18, 2019. To resubmit by the end of August 2020.
XIPERE (Suprachoroidal CLS-TA)
Macular edema associated with non-infectious uveitis
Approval announced March 2, 2018.
ULTRA - 7 days
Contact lens
CRL issued July 12, 2019. NDA resubmitted in December 2019.
EM-100
Allergic conjunctivitis
Phase 2 data met primary endpoint - March 31, 2020.
Rifaximin
Overt hepatic encephalopathy
Phase 3 data due 2020.
IDP-124
Atopic Dermatitis
Phase 2/3 trial to commence 1H 2020.
Rifaximin
Crohn's disease
Phase 2 enrolment to commence 1H 2020.
Rifaximin
Small intestinal bacterial overgrowth (SIBO)
Phase 3 trial ongoing.
IDP-126
Acne
Prooof of concept trial initiated 1H 2019.
IDP-131
Psoriasis
Cardiovascular data due 2020. Phase 2 trial to commence 2020.
Amiselimod S1P6 Modulator

Latest News

  1. Bausch Health Companies Inc. Will Hold Virtual Annual Meeting Of Shareholders On April 28

    LAVAL, Quebec, April 2, 2020 /PRNewswire/ -- Bausch Health Companies Inc. (TSX:BHC) ("Bausch Health" or the "Company") announced today that, due to the emerging public health impact of the COVID-19

  2. Bausch Health Announces Favorable Topline Results From Study Evaluating Investigative Formulation of Rifaximin SSD IR to Treat Overt Hepatic Encephalopathy

    Study Arm Evaluating 40 MG BID of Rifaximin SSD IR In Combination with Standard of Care Therapy Met Primary Endpoint LAVAL, Quebec, March 31, 2020 /PRNewswire/ -- Bausch Health Companies Inc. (TSX:BHC) ("Bausch

  3. Bausch Health Donates Health Care Products And Supplies Through Bausch Foundation In Response To COVID-19 Pandemic

    LAVAL, Quebec, March 24, 2020 /PRNewswire/ -- Bausch Health Companies Inc. (TSX:BHC) ("Bausch Health" or the "Company") today outlined several initiatives the Company is taking to contribute to the fight

  4. Bausch Health To Reduce Debt By Approximately $100 Million Using Cash Generated From Operations

    LAVAL, Quebec, March 13, 2020 /PRNewswire/ -- Bausch Health Companies Inc. (TSX:BHC) ("Bausch Health" or the "Company") today announced it will reduce debt by approximately $100 million through the

  5. Bausch Health Announces It Will No Longer Pursue Proposed Refinancing Transaction And Also Announces Cancellation Of Previously Delivered Notice Of Conditional Redemption

    LAVAL, Quebec, March 2, 2020 /PRNewswire/ -- Bausch Health Companies Inc. (TSX:BHC) ("Bausch Health" or the "Company") announced today that, due to market conditions, it has determined to not pursue the

  6. Bausch Health Announces It Is Seeking A Refinancing Amendment To Its Existing Credit Agreement And Conditional Redemption Of Existing Senior Secured Notes

    LAVAL, Quebec, Feb. 19, 2020 /PRNewswire/ -- Bausch Health Companies Inc. (TSX:BHC) ("Bausch Health" or the "Company") announced today that it is seeking to amend and refinance its existing credit

  7. Bausch Health Companies Inc. Announces Fourth-Quarter And Full-Year 2019 Results And Provides 2020 Guidance

    LAVAL, Quebec, Feb. 19, 2020 /PRNewswire/ --  Fourth-Quarter 2019 Financial Results Revenues of $2.224 Billion GAAP Cash Generated from Operations of $234 Million GAAP Net Loss of $1.516 Billion Adjusted EBITDA

  8. Ortho Dermatologics Launches Telemedicine on Dermatology.com, U.S. Cash-Pay Prescription Program

    Patients Can Now Use Site to Consult with Qualified Health Care Professionals On-Demand, Order and Potentially Receive Dermatologist-Recommended Skin Care Products BRIDGEWATER, N.J., Feb. 18, 2020 /PRNewswire/ --

  9. Bausch Health To Reduce Debt By $100 Million Using Cash Generated From Operations

    LAVAL, Quebec, Feb. 12, 2020 /PRNewswire/ -- Bausch Health Companies Inc. (TSX:BHC) ("Bausch Health" or the "Company") announced today it will reduce debt by $100 million through the redemption of

  10. Bausch Health Announces Participation In Upcoming Investor Conferences

    LAVAL, Quebec, Feb. 4, 2020 /PRNewswire/ -- Bausch Health Companies Inc. (TSX:BHC) today announced that the Company will participate in three investor conferences. Paul S. Herendeen, executive vice president and chief

  11. Bausch + Lomb And Prevent Blindness Join Together To Raise Awareness And Provide Educational Resources For February's Age-Related Macular Degeneration Awareness Month

    Organizations Launch Social Media Campaign and Offer SightMatters.com to Provide People with AMD and Caregivers with Educational Information, AMD Action Plan and More BRIDGEWATER, N.J., and CHICAGO, Feb. 3, 2020

  12. Ortho Dermatologics Opens 2020 Aspire Higher Scholarship Program

    Students Treated for Dermatologic Conditions Can Apply for the Scholarship Through April 27, 2020 LAVAL, Quebec, Feb. 3, 2020 /PRNewswire/ -- Bausch Health Companies Inc. (TSX:BHC) and its dermatology business, Ortho

  13. Bausch Health and Clearside Biomedical Announce Publication of PIVOTAL Phase 3 Data ON XIPERETM (triamcinolone acetonide suprachoroidal injectable suspension) in Ophthalmology

    LAVAL, Quebec and ALPHARETTA, Ga., Jan. 28, 2020 /PRNewswire/ -- Bausch Health Companies Inc. (TSX:BHC) ("Bausch Health") and Bausch + Lomb, its leading global eye health business, and Clearside Biomedical,

  14. Bausch Health Companies Inc. Will Release Fourth-Quarter and Full-Year 2019 Financial Results on February 19

    LAVAL, Quebec, Jan. 16, 2020 /PRNewswire/ -- Bausch Health Companies Inc. (TSX:BHC) ("Bausch Health") will release its fourth-quarter and full-year 2019 financial results on Wednesday, Feb. 19, 2020. Bausch

  15. Bausch Health Publishes Company Update for the 38th Annual J.P. Morgan Healthcare Conference

    LAVAL, Quebec, Jan. 13, 2020 /PRNewswire/ -- Bausch Health Companies Inc. (TSX:BHC) (the "Company") has published a brief company update presentation designed to complement remarks that will be provided by

  16. Ortho Dermatologics Announces Publication Of Pivotal Phase 3 Data On ARAZLO™ (tazarotene) Lotion, 0.045% In The Journal Of Drugs In Dermatology (JDD)

    ARAZLO Lotion Demonstrated Statistically Significant Superiority Over Placebo with Favorable Efficacy, Safety and Tolerability Profile Post Hoc Analysis of the Two Phase 3 Studies Also Published in JDD BRIDGEWATER,

  17. Bausch + Lomb Launches Expanded Parameters for Biotrue® ONEday for Astigmatism Daily Disposable Contact Lenses

    Lens Parameters Expanded by Nearly 60 percent, Providing Eye Care Professionals the Broadest Offering Among All Daily Disposable Toric Lenses   BRIDGEWATER, N.J., Jan. 6, 2020 /PRNewswire/ -- Bausch + Lomb, a leading

  18. Bausch Health To Participate At The 38th Annual J.P. Morgan Healthcare Conference

    LAVAL, Quebec, Jan. 6, 2020 /PRNewswire/ -- Bausch Health Companies Inc. (TSX:BHC) today announced that Joseph C. Papa, chairman and chief executive officer, is scheduled to participate at the 38th Annual J.P. Morgan

  19. Bausch Health Licenses Novaliq's NOV03 Investigational Treatment For Dry Eye Disease Associated With Meibomian Gland Dysfunction

    LAVAL, Quebec and HEIDELBERG, Germany, Dec. 20, 2019 /PRNewswire/ --  Bausch Health Companies Inc. (TSX:BHC) ("Bausch Health") and Bausch + Lomb, its leading global eye health business, and Novaliq GmbH, a

  20. Bausch Health Announces Resolution Of BRYHALI® (Halobetasol Propionate) Lotion, 0.01%, Intellectual Property Litigation With Glenmark

    Ortho Dermatologics Will Maintain Market Exclusivity for BRYHALI Lotion Until 2026¹ LAVAL, Quebec, Dec. 20, 2019 /PRNewswire/ -- Bausch Health Companies Inc. (TSX:BHC) ("Bausch Health" or the "Company")

  21. Bausch + Lomb Announces VYZULTA® (Latanoprostene Bunod Ophthalmic Solution 0.024%) Now Publicly Covered Under the Ontario Public Drug Benefit (ODB) Program

    LAVAL, QC, Dec. 19, 2019 /CNW Telbec/ - Bausch + Lomb, a leading global eye health business of Bausch Health Companies Inc. (NYSE:BHC) (TSX:BHC), today announced that VYZULTA® (latanoprostene bunod ophthalmic solution,

  22. FDA Approves Ortho Dermatologics' ARAZLOTM (Tazarotene) Lotion, 0.045%, For Acne Vulgaris

    First Tazarotene Acne Treatment Approved in Lotion Formulation BRIDGEWATER, N.J., Dec. 19, 2019 /PRNewswire/ -- Bausch Health Companies Inc. (TSX:BHC) and its dermatology business, Ortho Dermatologics, one of the

  23. Bausch Health Announces Conditional Redemption Of Existing Senior Notes

    LAVAL, Quebec, Dec. 18, 2019 /PRNewswire/ -- Bausch Health Companies Inc. (TSX:BHC) ("Bausch Health" or the "Company") announced that it issued today a conditional notice of redemption for $1.240 billion

  24. Bausch Health Announces Pricing of Private Offering of Senior Notes

    LAVAL, Quebec, Dec. 17, 2019 /PRNewswire/ -- Bausch Health Companies Inc. (TSX:BHC) ("Bausch Health" or the "Company") announced today that it has priced its previously announced offering of

  25. Bausch + Lomb Initiates Clinical Trial Evaluating New Cohesive Ophthalmic Viscosurgical Device (OVD) For Use In Cataract Surgery

    Investigational OVD Now the Second in the Company's Pipeline BRIDGEWATER, N.J., Dec. 17, 2019 /PRNewswire/ -- Bausch + Lomb, a leading global eye health business of Bausch Health Companies Inc. (NYSE/TXS: BHC),

  26. Bausch Health Announces Launch Of Private Offering Of Senior Notes

    LAVAL, Quebec, Dec. 17, 2019 /PRNewswire/ -- Bausch Health Companies Inc. (TSX:BHC) ("Bausch Health" or the "Company") announced today that it has launched an offering of a combined

  27. Bausch + Lomb Introduces enVista® Toric MX60ET Intraocular Lens With StableFlex™ Technology

    BRIDGEWATER, N.J., Dec. 11, 2019 /PRNewswire/ -- Bausch + Lomb, a leading global eye health business of Bausch Health Companies Inc. (NYSE/TSX: BHC), today announced the introduction of the enVista® toric MX60ET

  28. Bausch + Lomb And TerraCycle Announce Donation Of New Custom Training Modules Incorporating Used Contact Lens Materials To Guide Dog Foundation

    Benches, Tables, Waste Stations and an Agility Ramp Will Help  Train Guide Dogs for the Blind or Visually Impaired BRIDGEWATER, N.J., Nov. 13, 2019 /PRNewswire/ -- Bausch + Lomb, a leading global eye

  29. Bausch Health Companies Announces Participation in Upcoming Investor Conferences

    LAVAL, Quebec, Nov. 11, 2019 /PRNewswire/ -- Bausch Health Companies Inc. (TSX:BHC) today announced that the Company will participate in three investor conferences. Joseph C. Papa, chairman and chief executive officer,

  30. Bausch Health Companies Inc. Announces Third-Quarter 2019 Results and Raises Full-Year Revenue and Adjusted EBITDA (non-GAAP) Guidance Ranges

    LAVAL, Quebec, Nov. 4, 2019 /PRNewswire/ -- Third-Quarter 2019 Financial Results Revenues of $2.209 Billion GAAP Net Loss of $49 Million Adjusted EBITDA (non-GAAP)1 of $942 Million GAAP Cash Generated from Operations of

  31. Salix Announces Issuance of an Additional XIFAXAN® Patent

    LAVAL, Quebec, Oct. 31, 2019 /PRNewswire/ -- Bausch Health Companies Inc. (TSX:BHC) ("Bausch Health" or the "Company") and its gastroenterology business, Salix Pharmaceuticals, ("Salix"), one of

  32. Salix Pharmaceuticals Announces Inaugural Scholarship Program To Commemorate Its 30th Anniversary

    Applications For The Salix Gastrointestinal Health Scholars Program Will Be Accepted Beginning Nov. 1, 2019 BRIDGEWATER, N.J., Oct. 30, 2019 /PRNewswire/ -- Bausch Health Companies Inc. (TSX:BHC) and its

  33. Salix Pharmaceuticals to Present New Clinical Data at the American College of Gastroenterology (ACG) Annual Meeting

    TRULANCE® (plecanatide) Poster Presentation Recognized with Presidential Poster Award Distinction BRIDGEWATER, N.J., Oct. 28, 2019 /PRNewswire/ -- Bausch Health Companies Inc. (TSX:BHC) and its gastroenterology

  34. Bausch + Lomb Introduces PreserVision® AREDS 2 Formula Minigel Eye Vitamins

    Now Available at Major U.S. Retailers BRIDGEWATER, N.J., Oct. 21, 2019 /PRNewswire/ -- Bausch + Lomb, a leading global eye health company and wholly owned subsidiary of Bausch Health Companies Inc. (NYSE/TXS: BHC),

  35. Bausch Health's Ortho Dermatologics Business To Present Data At The Fall Clinical Dermatology Conference

    18 Poster Presentations on Investigational and Existing Products LAVAL, Quebec, Oct. 15, 2019 /PRNewswire/ -- Bausch Health Companies Inc. (TSX:BHC) and its dermatology business, Ortho Dermatologics, one of the largest

  36. Ortho Dermatologics Announces 2019 Aspire Higher Scholarship Recipients

    $10,000 Scholarships Awarded to Nine Students Affected by Dermatologic Conditions LAVAL, Quebec, Oct. 10, 2019 /PRNewswire/ -- Bausch Health Companies Inc. (TSX:BHC) and its dermatology business, Ortho Dermatologics,

  37. Bausch + Lomb Announces New Scientific And Clinical Analyses To Be Presented During The American Academy Of Ophthalmology And American Academy Of Optometry Annual Meetings

    BRIDGEWATER, N.J., Oct. 7, 2019 /PRNewswire/ -- Bausch + Lomb, a leading global eye health company and wholly owned subsidiary of Bausch Health Companies Inc. (NYSE/TXS: BHC), today announced that 14 new scientific

  38. Bausch Health Companies Inc. Will Release Third-Quarter 2019 Financial Results on November 4

    LAVAL, Quebec, Oct. 4, 2019 /PRNewswire/ -- Bausch Health Companies Inc. (TSX:BHC) ("Bausch Health") will release its third-quarter 2019 financial results on Monday, Nov. 4, 2019. Bausch Health will host a

  39. Bausch Health Files Lawsuit Against Sandoz For Infringement Of Patents Protecting XIFAXAN® 550 mg Tablets

    BRIDGEWATER, N.J., Oct. 1, 2019 /PRNewswire/ -- Bausch Health Companies Inc. (TSX:BHC) ("Bausch Health" or the "Company") along with its wholly owned subsidiary, Salix Pharmaceuticals ("Salix"),

  40. Bausch Health Releases 2018 Corporate Social Responsibility Report

    Second Annual Report Reinforces the Company's Continued Commitment to Responsible, Ethical and Sustainable Operations LAVAL, Quebec, Sept. 10, 2019 /PRNewswire/ -- Bausch Health Companies Inc. (TSX:BHC)

  41. Bausch Health To Reduce Debt By Approximately $200 Million Using Cash Flow From Operations

    LAVAL, Quebec, Sept. 3, 2019 /PRNewswire/ -- Bausch Health Companies Inc. (TSX:BHC) ("Bausch Health" or the "Company") today announced it will reduce debt by approximately $200 million through the

  42. Bausch Health Companies Announces Participation In Upcoming Investor Conferences

    LAVAL, Quebec, Aug. 29, 2019 /PRNewswire/ -- Bausch Health Companies Inc. (TSX:BHC) today announced that the Company will participate in three investor conferences. Paul S. Herendeen, executive vice president and chief